Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › cladribine

cladribine

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of cladribine

19 trials tracked of cladribine: 3 in phase 3 or 4.

19Trials tracked
3Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 3 Phase 2 12 Phase 1 2 Other / NA 2
  1. Phase 3 A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) Completed
  2. Phase 3 Oral Cladribine in Early Multiple Sclerosis (MS) Completed
  3. Phase 3 CLARITY Extension Study Completed
  4. Phase 2 Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia Completed
  5. Phase 2 Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma Completed
  6. Phase 2 Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed
Show 13 more trials
  1. Phase 2 Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma Completed
  2. Phase 2 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed
  3. Phase 2 Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia Completed
  4. Phase 2 Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS Completed
  5. Phase 2 A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) Completed
  6. Phase 2 Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm Completed
  7. Phase 2 Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Completed
  8. Phase 2 Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm Completed
  9. Phase 2 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Completed
  10. Phase 1 Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects Completed
  11. Phase 1 Effects of Cladribine Tablets on the PK of Microgynon® Completed
  12. N/A Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS) Completed
  13. N/A A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS) Completed

Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Oral cladribine reshapes CSF immune cell composition in relapsing multiple sclerosis
Neurology RCT
Oral cladribine reshapes CSF immune cell composition in relapsing multiple sclerosis Cladribine therapy changes immune cells in fluid from the brain in a small MS study
This single-site phase IV clinical trial used single-cell sequencing on CSF and blood from 13 individuals with relapsing MS before and after…
Cladribine therapy reshapes immune cells in the brain's fluid by reducing harmful memory B cells while boosting protective Treg cells in mul…
Apr 17, 2026
Cladribine tablets maintain stable patient-reported outcomes in highly active MS over 52 weeks
Neurology Cohort
Cladribine tablets maintain stable patient-reported outcomes in highly active MS over 52 weeks Your Fitness Tracker Could Now Help Manage Your Multiple Sclerosis
An interim analysis of a prospective observational study in 190 Italian patients with highly active MS found that cladribine tablets maintai…
Multiple sclerosis patients using cladribine tablets maintain physical function while wearables track symptoms continuously between doctor v…
Frontiers Apr 12, 2026